Immunological backbone of uveal melanoma: Is there a rationale for immunotherapy?

Alessandra Cassano, Guido Rindi, Emilio Bria, Maria Antonietta Blasi, Giampaolo Tortora, Ernesto Rossi, Giovanni Schinzari, Brigida Anna Maiorano, Monica Maria Pagliara, Vincenzo Fiorentino, Gianluigi Petrone, Ilaria Grazia Zizzari, Marianna Nuti

Research output: Contribution to journalArticle

11 Citations (Scopus)


No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immunotherapy. The immunological features of mUM were reviewed in order to understand if immunotherapy could still play a role for this disease.
Original languageEnglish
Pages (from-to)1055-1066
Number of pages12
Publication statusPublished - 2019


  • Checkpoint inhibitors
  • IDO
  • Immunotherapy
  • Ipilimumab
  • Nivolumab
  • PD-L1
  • Pembrolizumab
  • Uveal melanoma


Dive into the research topics of 'Immunological backbone of uveal melanoma: Is there a rationale for immunotherapy?'. Together they form a unique fingerprint.

Cite this